Sinopharma

EqualOcean and Skepsos Sign Strategic Cooperation Memorandum of Understanding

On May 20, 2025, Beijing EO Technology Co.,Ltd and the Greater Paris Health Industry Park (Skepsos) officially signed a Memorandum of Understanding on Strategic Cooperation in Beijing.

Capital Frenzy: AI Healthcare's Inflection Point

Is AI healthcare now approaching its own “DeepSeek Moment” as it rides a new wave of momentum?

How Can MedTech Leverage Technological Innovation and Strategic Precision to Go-Global

How Can MedTech Companies Leverage Technological Innovation and Strategic Precision to Expand Globally? | Highlights from GGF2024

CelcomDigi Berhad and AmBank Sign MOU to Drive Digital Healthcare Transformation

CelcomDigi Berhad today announced the signing of a three-year Memorandum of Understanding (MoU) with AmBank (M) Berhad and AmBank Islamic Berhad, with the aim of empowering healthcare providers in Malaysia through digital healthcare solutions.

SINOVAC Plans to Invest USD 100 Mn in Brazil Starting This Year

EqualOcean has learned that on June 4, Vice President of the Federative Republic of Brazil and Minister of Development, Industry, Trade, and Services, Geraldo Alckmin, met with SINOVAC(科兴) Chairman, President, and CEO Yin Weidong(尹卫东) in Beijing.

Cellatopia Secures Nearly CNY Ten Mn in Seed Funding

EqualOcean has learned that Cellatopia(喜同生物), a biotechnology company based in Suzhou, recently announced the successful securing of nearly CNY ten million in seed funding. The funding was primarily led by Suzhou Shishangbai Venture Capital(苏州石上柏创业合伙企业) and followed by institutions such as Suzhou Nuowei Venture Investment Limited(苏州诺为创业投资有限公司).

Hengrui's MSCI ESG Rating Upgraded to A

Hengrui, as one of the leading pharmaceutical companies in innovation, has achieved continuous improvement in its MSCI ESG rating to "A" level, placing it at the forefront of the pharmaceutical industry in China.

Lanja has completed the Series A funding of hundred millions CNY

Shanghai Lanja Medical Technology Co., Ltd (“Lanja”) recently has announced the completion of the Series A funding of hundred millions CNY.

MGI Tech: Lead Life Science Through Intelligent Innovation

In the dynamic realm of bioscience, MGI Tech Co., Ltd. (MGI) has emerged as a torchbearer, captivating attention with its trailblazing achievements and relentless dedication to innovation.

RabPharma has completed the Series A+ funding of hundred millions CNY

Zhongshan RabPharma Biopharmaceutical Co., Ltd. (“RabPharma”) recently has announced the completion of the Series A+ funding of hundred millions CNY.

Powertight has completed a pre-Series A funding of hundred millions CNY

Powertight Biotechnology (Hangzhou) Co., Ltd. (“Powertight”) recently has announced the completion of a pre-Series A funding of hundred millions CNY.

Foremed Legend has completed the pre-Series A+ funding

Suzhou Foremed Legend Medical Technology Company, Ltd. (“Foremed Legend”) recently has announced the completion of pre-Series A+ funding.

Bioprofile completed a Series A funding of hundred millions CNY

Shanghai Bioprofile Technology Company, Ltd. (“Bioprofile”) recently has announced the completion of hundred millions of CNY in Series A funding.

CSH Medical completed a Series A+ funding of nearly one hundred million CNY

CSH Medical Equipment (Shanghai) Co., Ltd (“CSH Medical”) recently has announced the completion of nearly one hundred million CNY in Series A+ funding.

Mateside has completed the first round of financing

Zhejiang Mateside Medical Device Technology Co., Ltd. (“Mateside”) recently has announced the completion of the first round of nearly 100 million CNY financing.

Milestone Biotech has completed a Series A funding of over a hundred million CNY

Milestone Biotechnologies Co., Ltd. (“Milestone Biotech”) recently has announced the completion of a Series B2 funding of over a hundred million CNY.

Bostal has completed a Series B2 funding of hundred millions CNY

Bostal Drug Delivery Co., Ltd. (“Bostal”) recently has announced the completion of a Series B2 funding of hundred millions CNY.

AI Pharmaceutical R&D Company DP Technology Raises New Round of Over CNY 700 Mn Financing

EqualOcean has learned that DP Technology（深势科技）, an AI pharmaceutical research company, has recently successfully completed a funding round of over CNY 700 million. Investors in this round include Zhongyuan Capital（众源资本）, MSA Capital（和玉资本）, Loyal Valley Capital（正心谷资本）, Evergreen Scitech Delta（深势科技）, and many other industry-specific investors, with Lighthouse Capital（光源资本） serving as the exclusive financial advisor.

Saints Sages has completed the Series B funding

Shanghai Saints Sages Surgical Co., Ltd. (“Saints Sages”) recently has announced the completion of the Series B funding, Qiming Venture Partners (启明创投) is the largest institutional investor.

Cascade completed a Series A funding of 140 million CNY

Cascade (Shanghai) Pharmaceutical, Inc (“Cascade”) recently announced the completion of 140 million CNY in Series A funding.